Vofatamab

Drug Overview

Vofatamab (also known as B-701) is an investigational, fully human monoclonal antibody designed to target the Fibroblast Growth Factor Receptor 3 (FGFR3). It is a precision medicine agent primarily being developed for the treatment of Urothelial Carcinoma (bladder cancer), particularly in patients whose tumors harbor specific FGFR3 mutations or fusions.

In the clinical landscape of March 2026, vofatamab is recognized as a “pathway-selective” inhibitor. While other approved drugs (like erdafitinib) inhibit multiple FGFR receptors (FGFR1, 2, 3, and 4), vofatamab is specifically engineered to be a selective FGFR3 antagonist. This selectivity is intended to maintain high anti-tumor activity while potentially reducing the off-target toxicities—such as hyperphosphatemia—associated with broader FGFR inhibitors.

• Generic Name: Vofatamab.
• Code Name: B-701.
• Drug Class: Monoclonal Antibody; FGFR3 Inhibitor.
• Mechanism: Binds to the extracellular domain of FGFR3, blocking ligand binding and downstream signaling.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, vofatamab is not FDA-approved. It has been studied in Phase 1 and Phase 2 trials, often in combination with immunotherapy.

What Is It and How Does It Work? (Mechanism of Action)

Vofatamab targets the FGFR3 signaling pathway, which is frequently “hyper-activated” in bladder cancer. This pathway normally regulates cell growth and survival, but when mutated, it sends constant signals for the cancer to multiply.

1. Selective Receptor Blockade

FGFR3 exists on the surface of many bladder cancer cells. Vofatamab is a large molecule (antibody) that specifically sits on the extracellular domain of this receptor.

• Ligand Competition: It prevents natural growth factors (ligands) from attaching to the receptor.
• Signal Silencing: By blocking the receptor, vofatamab shuts down the downstream MAPK and PI3K/AKT pathways, which are the “engines” driving the tumor’s growth.

2. Antibody-Dependent Cellular Cytotoxicity (ADCC)

Because vofatamab is a monoclonal antibody, it may also work by “flagging” the cancer cell for destruction by the patient’s own immune system.

• Immune Recruitment: Natural Killer (NK) cells recognize the vofatamab antibody bound to the tumor and can directly attack the cell.
• Immunotherapy Synergy: Research suggests that vofatamab can turn “cold” tumors (those that hide from the immune system) into “hot” tumors, making them more susceptible to Checkpoint Inhibitors like pembrolizumab.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for vofatamab.

Clinical research through 2026 has primarily focused on:

• Metastatic Urothelial Carcinoma: Especially in patients who have failed platinum-based chemotherapy.
• FGFR3-Mutated Bladder Cancer: Targeted specifically at patients with the S249C mutation or FGFR3-TACC3 fusions.
• Achondroplasia: Interestingly, because FGFR3 also plays a role in bone growth, vofatamab has been investigated for its potential to improve bone growth in children with this form of dwarfism.

Dosage and Administration Protocols

As an investigational agent, dosing is strictly determined by clinical trial protocols (such as the FIERCE trials).

Clinical Efficacy and Research Results

As of early 2026, results from the FIERCE-21 and FIERCE-22 trials have provided significant insights:

• Response Rates: In patients with FGFR3 mutations/fusions, the combination of vofatamab and pembrolizumab showed a higher objective response rate (ORR) than would be expected with pembrolizumab alone.
• The “Wild-Type” Effect: Surprisingly, some activity was also seen in patients without FGFR3 mutations, suggesting the drug may also work by inhibiting the “wild-type” receptor that the tumor uses for survival.
• Safety Advantage: Compared to small-molecule FGFR inhibitors, vofatamab has shown a lower incidence of hyperphosphatemia (high phosphate in the blood), which is a common and difficult-to-manage side effect of broader inhibitors.

Safety Profile and Side Effects

Vofatamab is generally well-tolerated, with a side effect profile distinct from traditional chemotherapy and other FGFR inhibitors.

Common Side Effects (>20%):

• Fatigue: The most commonly reported systemic symptom.
• Gastrointestinal: Nausea and occasional diarrhea.
• Infusion-Related Reactions: Fever, chills, or rash occurring during or shortly after the IV infusion.

Specific FGFR-Related Side Effects:

• Dry Skin and Brittle Nails: Common to the entire class of FGFR inhibitors.
• Ocular Toxicity: Rare reports of dry eyes or blurry vision, though less frequent than with pan-FGFR inhibitors.
• Liver Enzyme Elevation: Mild increases in AST/ALT, requiring periodic blood monitoring.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, vofatamab is a critical tool for studying “Skeletal Dysplasia.” Because mutations in FGFR3 are the primary cause of achondroplasia (dwarfism), researchers are using vofatamab to understand how the receptor inhibits the proliferation of Chondrocytes (cartilage-forming cells) in the growth plate. In 2026, there is also intense interest in “Clonal Evolution.” Scientists are studying how bladder cancer cells “evolve” to become resistant to vofatamab, often by switching their dependence from FGFR3 to other growth pathways like ERBB2 or EGFR.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Molecular Testing: Patients should ideally undergo genomic sequencing (NGS) to confirm the presence of an FGFR3 mutation or fusion.
• Ocular Baseline: A baseline eye exam is often recommended to monitor for potential retinal changes.

“Do’s and Don’ts” List:

• DO report any changes in vision or significant skin peeling immediately to your oncology team.
• DO keep up with bi-weekly infusions; the drug’s half-life is designed for a 14-day schedule.
• DON’T confuse vofatamab with other FGFR inhibitors like erdafitinib; vofatamab is an antibody (IV), whereas erdafitinib is a pill (oral).
• DON’T ignore infusion-site pain or redness, as this may indicate a mild infusion reaction that can be managed with pre-medications like diphenhydramine.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Vofatamab (B-701) is an investigational agent and is not approved by the U.S. FDA for any indication. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.